Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.

@article{Ujjani2011EfficacyOB,
  title={Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial.},
  author={Chaitra Ujjani and Bruce D Cheson},
  journal={Future oncology},
  year={2011},
  volume={7 1},
  pages={9-14}
}
B-cell malignancies, including B-cell non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), are the most common hematologic malignancies in the western world. Although excellent response rates are achieved with standard chemoimmunotherapy, patients often relapse and additional treatment is necessary. Bendamustine, a unique cytotoxic agent with alkylating and antimetabolite properties, has been used for decades in Germany for NHL, CLL and multiple myeloma. In 2008, bendamustine… CONTINUE READING